Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified DEB-TACE plus lenvatinib and camrelizumab for unresectable large hepatocellular carcinoma
ChiCTR2300076540Phase 4Not yet recruiting
- Sponsor
- Linyi Cancer Hospital
- Start
- Oct 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenvatinib, camrelizumab and epirubicin in hepatocellular carcinoma (HCC), sponsored by Linyi Cancer Hospital. Primary endpoint: Objective response rate. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
lenvatinibcamrelizumabepirubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300076540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076540.